[Comparison of the efficacy of 1% XXXX cream twice a day with 1% @entity45341 cream once a day for the treatment of superficial dermatophytoses].

@entity1 @entity4013 @entity12285 @entity2794 @entity45341
Different clinical studies have demonstrated @entity45341 's efficacy in the treatment of superficial dermatomycoses when administered either @entity2794 or @entity2794 for four weeks. The aim of the present study was to compare both dosing schedules for the treatment of superficial dermatomycoses. In this randomized, controlled, double blind study, we included 84 @entity1 suffering superficial @entity4013 (confirmed by microscopic examination (KOH) and culture) susceptible for topical monotherapy. Forty-one @entity1 received @entity45341 1% @entity2794 ( @entity2794 ) and forty-three @entity2794 ( @entity2794 ) for four weeks. The efficacy of treatment was evaluated by clinical and mycological criteria at the end of treatment (D28) and after four weeks without treatment (D58). Clinical and mycological cure rates on D28 were 50% with @entity2794 and 65% with @entity2794 treatment. Only considering clinical evaluation, clinical cure rates on D28 were 63% ( @entity2794 ) and 70% ( @entity2794 ). Also, clinical and mycological cure rates on D56 were 65% with @entity2794 and 72% with @entity2794 treatment. Only considering clinical evaluation, clinical cure rates on D56 were of 68% ( @entity2794 ) and 72% ( @entity2794 ). The overall tolerability was similar in both treatment groups. The efficacy assessment at the end of treatment (D28) and four weeks after treatment discontinuation (D56) showed that the @entity2794 treatment is not inferior to the @entity2794 treatment, with similar clinical and mycological cure rates and clinical cure rates in both cases. The @entity2794 administration of @entity45341 @entity12285 % is the most appropriate dosing schedule as it provides the same efficacy, it improves @entity1 's compliance and the cost per day of treatment.
